Business
TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual Meeting
Company to host a virtual KOL event to discuss highlights from the meeting on Thursday, May 19, 2022, at 4:30 p.m. ET WALTHAM, Mass., May 02, 2022 (GLOBE
About this update from Tscan Therapeutics, Inc.
[{"type":"text","content":"Company to host a virtual KOL event to discuss highlights from the meeting on Thursday, May 19, 2022, at 4:30 p.m. ET\nWALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of three abstracts at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held from May 16-19, 2022, both in Washington D.C. and virtually. Following the meeting, TScan will host a virtual KOL event on Thursday, May 19, 2022, at 4:30 p.m. ET to discuss the presentations and plans for its solid tumor program. Details for joining the live event can be found below. Poster presentations: Title: Discovery of TSC-200-A02: A natural HPV16 E7-specific TCR-T cell therapy candidate for the treatment of HPV-positive solid tumors Presenter: Gavin MacBeath Poster Number: M-198 Abstract Number: 317 Session: Cancer – Immunotherapy, Cancer Vaccines I Date & Time: Monday, May 16, 2022 5:30-6:30 p.m. ET Location: Hall D Summary: Human papilloma virus (HPV)16 E7 oncoprotein is homogenously expressed in every tumor cell of HPV16 positive tumors, is essential for tumor cell survival, and is not expressed by healthy tissues. Using TScan’s proprietary ReceptorScan platform, the Company identified a lead TCR. The lead TCR showed comparable preclinical activity to a therapeutic TCR from NCI, that has previously shown a 50% objective response rate in a Phase I clinical trial. No allo-reactivity was observed for the HLAs tested and only a few putative off-targets were identified using our genome-wide SafetyScan platform. The lead TCR showed no reactivity to primary healthy tissues expressing these putative off-targets during in vitro co-culture experiments indicating minimal off-tumor reactivity risk. To further enhance the function of the therapeutic T cell product, TScan is designing a transposon-based vector that can deliver the TCR gene, along with the genes for CD8α/β and dominant-negative form of TGFβRII, into both CD4+ and CD8+ T cells. The resulting TCR-T cell therapy candidate, TSC-200-A02, is expected to complete IND-enabling studies in the second half of 2022. These results validate the use of ReceptorScan...